Table 3.
All statistically significant univariate and adjusted odds ratios associated with kidney failure due to anti-GBM nephritis (positive outcome control). Odds ratios were considered statistically significant if p-values were less than 0.000862 after Bonferroni correction (58 tests). Adjusted odds ratios were estimated from a multivariable logistic regression model that included a term for DR15, as DR15 had the strongest association with anti-GBM nephritis. Prevalence of each HLA serotype among cases (n=989) and designated race/ethnicity matched controls (n=14835) is also provided. Significant results are bolded.
| Serotypes | Odds Ratio (95% CI) | P-value | Adjusted Odds Ratio* (95% CI) | P-value | Prevalence among Anti-GBM cases (%) | Control Prevalence (%) |
|---|---|---|---|---|---|---|
| DR15 | 6.81 (5.91–7.85) | 5.26E-155 | ref | ref | 70.59 | 26.05 |
| DR51 | 6.27 (5.36–7.32) | 8.55E-118 | 0.63 (0.39–1.02) | 0.0606 | 71.29 | 28.38 |
| DQ6 | 3.93 (3.37–4.58) | 1.74E-68 | 0.81 (0.63–1.05) | 0.113 | 73.67 | 41.57 |
| B7 | 2.85 (2.5–3.25) | 1.33E-55 | 1.27 (1.1–1.47) | 0.00113 | 46.36 | 23.26 |
| DR52 | 0.41 (0.36–0.47) | 1.91E-36 | 0.68 (0.59–0.79) | 3.98E-07 | 40.16 | 62.12 |
| DQ8 | 2.06 (1.78–2.39) | 4.26E-22 | 3.12 (2.66–3.66) | 5.88E-45 | 32.46 | 18.89 |
| DR11 | 0.26 (0.2–0.34) | 1.15E-21 | 0.37 (0.28–0.49) | 4.26E-12 | 5.49 | 18.36 |
| DQ7 | 0.44 (0.37–0.52) | 2.55E-21 | 0.67 (0.56–0.8) | 8.42E-06 | 19.18 | 35.19 |
| DQ5 | 0.40 (0.33–0.49) | 1.40E-20 | 0.52 (0.42–0.63) | 5.59E-11 | 14.07 | 29.06 |
| Bw4 | 0.54 (0.48–0.62) | 1.50E-19 | 0.63 (0.55–0.72) | 4.02E-11 | 47.47 | 62.4 |
| DR7 | 0.40 (0.32–0.48) | 3.08E-19 | 0.56 (0.45–0.68) | 2.89E-08 | 11.05 | 23.9 |
| Cw7 | 2.01 (1.71–2.36) | 1.67E-17 | 1.33 (1.13–1.58) | 0.000806 | 68.62 | 52.07 |
| DR4 | 1.74 (1.53–1.99) | 8.82E-17 | 2.76 (2.39–3.18) | 1.24E-44 | 42.39 | 29.67 |
| DR13 | 0.44 (0.35–0.54) | 3.45E-15 | 0.62 (0.5–0.77) | 9.98E-06 | 10.58 | 21.37 |
| DQ2 | 0.56 (0.48–0.65) | 1.37E-13 | 0.83 (0.71–0.98) | 0.0269 | 26.33 | 38.96 |
| DR1 | 0.48 (0.39–0.59) | 3.46E-12 | 0.65 (0.53–0.81) | 0.000102 | 10.34 | 19.5 |
| Bw6 | 2.32 (1.82–2.95) | 1.15E-11 | 1.86 (1.45–2.38) | 9.25E-07 | 92.39 | 83.97 |
| B60 | 1.87 (1.54–2.26) | 1.69E-10 | 2.19 (1.79–2.68) | 2.98E-14 | 13.6 | 7.77 |
| B35 | 0.51 (0.41–0.63) | 4.65E-10 | 0.63 (0.51–0.79) | 4.09E-05 | 9.82 | 17.68 |
| Cw4 | 0.50 (0.4–0.62) | 8.34E-10 | 0.61 (0.48–0.76) | 1.67E-05 | 12.69 | 22.63 |
| DR14 | 0.29 (0.18–0.46) | 1.45E-07 | 0.43 (0.27–0.68) | 0.000348 | 1.93 | 6.32 |
| B44 | 0.65 (0.55–0.77) | 4.07E-07 | 0.75 (0.63–0.89) | 0.000871 | 18.32 | 25.59 |
| Cw16 | 0.29 (0.17–0.48) | 2.39E-06 | 0.35 (0.21–0.6) | 9.17E-05 | 2.09 | 6.88 |
| DR17 | 0.69 (0.58–0.82) | 3.24E-05 | 1.01 (0.84–1.21) | 0.935 | 16.44 | 22.24 |
| A3 | 1.33 (1.16–1.53) | 6.01E-05 | 1.01 (0.87–1.16) | 0.943 | 31.21 | 25.42 |
| DQ9 | 0.52 (0.38–0.72) | 9.48E-05 | 0.72 (0.52–1.01) | 0.0543 | 4.43 | 8.15 |
| Cw2 | 0.55 (0.39–0.76) | 0.000346 | 0.64 (0.46–0.9) | 0.0102 | 5.3 | 9.3 |
| Cw6 | 0.68 (0.55–0.85) | 0.000708 | 0.79 (0.63–0.99) | 0.042 | 13.11 | 18.1 |
| Cw10 | 1.41 (1.16–1.73) | 0.000721 | 1.75 (1.42–2.15) | 1.54E-07 | 17.02 | 12.67 |